Login

Financial Snapshot

Revenue
TTM
$7.438B
Gross Margin
TTM
37.45%
Net Income
TTM
$415.3M
Current Assets
2026 Q1
$5.254B
Current Liabilities
2026 Q1
$2.124B
Current Ratio
2026 Q1
247.36%
Total Assets
2026 Q1
$20.08B
Total Liabilities
2026 Q1
$14.62B
Book Value
2026 Q1
5.458B
Cash
2026 Q1
$702.0M
P/E
TTM
13.40
Free Cash Flow
TTM
$596.2M

Stock Price

Loading...
Market Cap: $5.5646 Billion

About Grifols SA

Grifols SA is a global specialty plasma therapeutics company that engages in the development, manufacturing, and distribution of a broad range of biological medicines based on plasma-derived proteins. The company is headquartered in Sant Cugat Del Valles, Barcelona and currently employs 25,258 full-time employees. The company went IPO on 2006-05-17. The firm organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.

Industry: Pharmaceutical Preparations

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support